Overview

The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

Status:
NOT_YET_RECRUITING

Trial end date:
2028-09-30

Target enrollment:

Participant gender:

Summary

A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis

Phase:

PHASE1

Details

Lead Sponsor:

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.